A RANDOMIZED PHASE (PH) 2 STUDY WITH EXPLORATORY BIOMARKER ANALYSIS OF FICLATUZUMAB (F) A HUMANIZED HEPATOCYTE GROWTH FACTOR (HGF) INHIBITORY MAB IN COMBINATION WITH GEFITINIB (G) VERSUS G IN ASIAN PATIENTS (PTS) WITH LUNG ADENOCARCINOMA (LA)
Other conference paper


Full Text
There are no full text file(s) associated with this record.

Times Cited
Web of Science10WOS source URL (as at 21/01/2021) Click here for the latest count

Other information
All Author(s) ListMok TSK, Park K, Geater SL, Agarwal S, Han M, Credi M, McKee K, Kuriyama N, Slichenmyer W, Tan EH
Name of Conference37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Start Date of Conference28/09/2012
End Date of Conference02/10/2012
Place of ConferenceVienna
Country/Region of ConferenceAustria
Journal nameAnnals of Oncology
Detailed descriptionorganized by European Society for Medical Oncology,
Year2012
Month9
Day1
Volume Number23
PublisherOxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY
Pages391 - 391
ISSN0923-7534
eISSN1569-8041
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-22-01 at 00:10